Identifying carriers of BRCA1 and BRCA2 pathogenic variants for cancer prevention (prophylactic surgery [9, 10]) and management of OC using new therapies (e.g. poly (ADP-ribose) polymerase inhibitors (PARPi) [11–16]) is being offered in medical genetic and gynecologic oncology settings. Here, BRCA1 is linked to cancer.